NRx Pharmaceuticals, Inc.

NRXP Healthcare Biotechnology

NRx Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million. In the quarter to June 2026, EPS grew 55.1% and free cash flow fell 142.6%, each against the same quarter a year earlier.

2.60 0.11 −4.06%
Market cap
$117.3M
P/E
0.0×
Fwd P/E
−12.8×
Dividend yield
—
F-score
n/a
Altman Z
−37.82
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
131.22% 125.92% 146.18% 170.77%

+8 more TTM periods

ROA
(120.41%) (251.78%) (344.70%) (391.21%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
618.36% 139.78% 145.86% 133.19%
Average Days of Receivables
22.15 0.00 0.00 0.00
Free Cash Flow per Share
(0.55) (0.46) (0.66) (0.56)
Free Cash Flow
(20.67) (14.93) (14.11) (12.50)
Other line items

Show all line items

Columns are period end dates